Barclays Raises Estimates on Citi (NYSE: C); Attractive Long-term Investment
Tweet Send to a FriendGet Alerts C Hot Sheet
Price: $51.45 +1.66%
Rating Summary:
18 Buy, 3 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
18 Buy, 3 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade C Now!
Barclays maintains an 'Overweight' on Citi (NYSE: C) price target of $46.00.
Analyst, Jason M. Goldberg, said, "Relative to our expectations, modestly lower-than-expected expenses (positive operating leverage continued) and loan loss provision (asset quality continued to improve), as well as a lower-than-anticipated tax rate, were able to more than offset a lower-than-projected net interest margin."
Goldberg raises FY12 EPS estimate from $3.85 to $4.25 and FY13 from $4.15 to $4.35.
For an analyst ratings summary and ratings history on Citi click here. For more ratings news on Citi click here.
Shares of Citi closed at $26.81 yesterday, with a 52 week range of $21.40-$116.09.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Jason M. Goldberg, said, "Relative to our expectations, modestly lower-than-expected expenses (positive operating leverage continued) and loan loss provision (asset quality continued to improve), as well as a lower-than-anticipated tax rate, were able to more than offset a lower-than-projected net interest margin."
Goldberg raises FY12 EPS estimate from $3.85 to $4.25 and FY13 from $4.15 to $4.35.
For an analyst ratings summary and ratings history on Citi click here. For more ratings news on Citi click here.
Shares of Citi closed at $26.81 yesterday, with a 52 week range of $21.40-$116.09.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Says Tesla (TSLA) 'Top Pick in U.S. Autos'
- SunPower (SPWR) Not Worth More than $13/Share, Says Goldman
- Goldman Sees Blockbuster Potential for Bristol-Myers Squibb's (BMY) Nivolumab (PD-1)
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT ChangeRelated Entities
Citi, Barclays
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
